Alnylam bets on 'gene silencing' to woo biotech investors

[riky]

Alnylam bets on 'gene silencing' to woo biotech investors

By Esha Dey and Pallavi Ail (Reuters) - A radical new treatment for genetic disorders has catapulted Alnylam Pharmaceuticals Inc into the crosshairs of investors seeking the next breakthrough name in biotechnology. The challenge for the Cambridge, Massachusetts-based company now is to prove that its 'gene silencing' technology can make the leap from the laboratory to the doctor's office and eclipse an alternative therapy already in use. Investors, for now, are betting that it will. A steady drip of positive trial data has helped to triple Alnylam's market value to more than $2. ...

Source: You are not allowed to view links. Register or Login